Bioverativ clinical trials
Acquired by Sanofi, Mar 8, 2018 · source ↗
The registry lists 16 studies whose lead sponsor is Bioverativ. 0 are recruiting or about to start. Per ClinicalTrials.gov, last updated Jul 28, 2026.
Before and after it joined Sanofi
- First submitted before Bioverativ became part of Sanofi
- 8
- First submitted after Bioverativ became part of Sanofi
- 8
- Unclear, or no submission date
- 0
By the date each study was first submitted to the registry. The registry lists today's sponsor name and keeps no history, so this says when a study was filed, not who filed it.
Status
- Completed
- 14
- Active, not recruiting
- 1
- Terminated
- 1
Phase
- Phase 3
- 7
- Phase 1
- 6
- Phase 2
- 3
- Phase 4
- 1
Where
- United States
- 14
- Germany
- 12
- United Kingdom
- 12
- Netherlands
- 11
- Italy
- 11
- France
- 10
Registry sponsor names on this page
- Bioverativ, a Sanofi company16 studies
Something wrong with this grouping? Tell us on the Sanofi page.
Studies
Recruiting first, then most recently updated. Showing 16 of 16. All Sanofi studies →
- Long-term Safety and Efficacy of Efanesoctocog Alfa (BIVV001) in Previously Treated Patients With Hemophilia AActive, not recruitingNCT04644575Phase 3
Sponsor listed in the registry: Bioverativ, a Sanofi company · First submitted after Bioverativ became part of Sanofi
- Proof-of-concept Study for SAR445088 in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)CompletedNCT04658472Phase 2
Sponsor listed in the registry: Bioverativ, a Sanofi company · First submitted after Bioverativ became part of Sanofi
- To Assess the Pharmacokinetics and Safety and Tolerability of Efanesoctocog Alfa (BIVV001)in Adults With Type 2N and 3 Von Willebrand Disease (VWD)CompletedNCT04770935Phase 1
Sponsor listed in the registry: Bioverativ, a Sanofi company · First submitted after Bioverativ became part of Sanofi
- A Safety and Tolerability Study of BIVV020 in Adults With Cold Agglutinin DiseaseCompletedNCT04269551Phase 1
Sponsor listed in the registry: Bioverativ, a Sanofi company · First submitted after Bioverativ became part of Sanofi
- A Phase 3 Open-label Interventional Study of Intravenous Recombinant Coagulation Factor VIII Fc-von Willebrand Factor-XTEN Fusion Protein, Efanesoctocog Alfa (BIVV001), in Patients With Severe Hemophilia ACompletedNCT04161495Phase 3
Sponsor listed in the registry: Bioverativ, a Sanofi company · First submitted after Bioverativ became part of Sanofi
- Safety, Efficacy and PK of BIVV001 in Pediatric Patients With Hemophilia ACompletedNCT04759131Phase 3
Sponsor listed in the registry: Bioverativ, a Sanofi company · First submitted after Bioverativ became part of Sanofi
- Safety and Tolerability Study in Adults With Cold Agglutinin Disease Previously Treated With SAR445088 or Never Treated With SAR445088TerminatedNCT04802057Phase 1
Sponsor listed in the registry: Bioverativ, a Sanofi company · First submitted after Bioverativ became part of Sanofi
- A Phase 2a Study Evaluating BIVV020 in Adults With Persistent/Chronic Immune Thrombocytopenia (ITP)CompletedNCT04669600Phase 2
Sponsor listed in the registry: Bioverativ, a Sanofi company · First submitted after Bioverativ became part of Sanofi
- A Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple- Dose BIVV009 in Participants With Chronic Immune Thrombocytopenia (ITP)CompletedNCT03275454Phase 1
Sponsor listed in the registry: Bioverativ, a Sanofi company · First submitted before Bioverativ became part of Sanofi
- A Study to Assess the Efficacy and Safety of BIVV009 (Sutimlimab) in Participants With Primary Cold Agglutinin Disease Without A Recent History of Blood TransfusionCompletedNCT03347422Phase 3
Sponsor listed in the registry: Bioverativ, a Sanofi company · First submitted before Bioverativ became part of Sanofi
- A Study to Assess the Efficacy and Safety of BIVV009 (Sutimlimab) in Participants With Primary Cold Agglutinin Disease Who Have a Recent History of Blood Transfusion (Cardinal Study)CompletedNCT03347396Phase 3
Sponsor listed in the registry: Bioverativ, a Sanofi company · First submitted before Bioverativ became part of Sanofi
- Safety, Tolerability and Activity of BIVV009 in Healthy Volunteers and Patients With Complement Mediated DisordersCompletedNCT02502903Phase 1
Sponsor listed in the registry: Bioverativ, a Sanofi company · First submitted before Bioverativ became part of Sanofi
- A Safety, Tolerability, and Pharmacokinetics Study of a Single Intravenous Injection of Recombinant Coagulation Factor VIII Fc - Von Willebrand Factor - XTEN Fusion Protein (rFVIIIFc-VWF-XTEN) (BIVV001) in Previously Treated Adults With Severe Hemophilia A (EXTEN-A)CompletedNCT03205163Phase 1/2
Sponsor listed in the registry: Bioverativ, a Sanofi company · First submitted before Bioverativ became part of Sanofi
- An Open Label Study to Determine the Safety and Efficacy of Replacement Factor VIII Protein (Known as rFVIIIFc) in Previously Untreated Males With Severe Hemophilia ACompletedNCT02234323Phase 3
Sponsor listed in the registry: Bioverativ, a Sanofi company · First submitted before Bioverativ became part of Sanofi
- A Study to Evaluate Efficacy of rFVIIIFc for Immune Tolerance Induction (ITI) in Severe Hemophilia A Participants With Inhibitors Undergoing the First ITI Treatment (verITI-8 Study)CompletedNCT03093480Phase 4
Sponsor listed in the registry: Bioverativ, a Sanofi company · First submitted before Bioverativ became part of Sanofi
- Study to Determine the Safety and Efficacy of rFIXFc in Previously Untreated Males With Severe Hemophilia BCompletedNCT02234310Phase 3
Sponsor listed in the registry: Bioverativ, a Sanofi company · First submitted before Bioverativ became part of Sanofi